Abstract
In August 2017, the FDA took historic action in granting the first approval of gene therapy to tisagenlecleucel. This landmark step brought CAR T-cell therapy to the commercial space and heralded a new era in managing refractory B-cell malignancies and FDA oversight of gene-modified therapies. See related article by O'Leary et al., p. 1142
Funding Information
  • American Society of Hematology (N/A)
  • Lymphoma Research Foundation (N/A)
  • National Center for Advancing Translational Sciences (UL1TR00457)